PepChile

Transportadores de Membrana para Peptidos

Categorías: Metodología de Investigación, Información General

Los transportadores de membrana facilitan el paso de peptidos a traves de barreras biologicas. Son relevantes para absorcion y distribucion.

Resumen Simplificado

PEPT1/PEPT2 transportan di/tripeptidos. Los transportadores ABC efflux pueden limitar absorcion.

Familia PEPT

PEPT transporters move peptides. PEPT1. SLC15A1. Intestinal. Apical membrane. High capacity. Low affinity. Absorptive. Di-tripeptides. Proton-coupled. Symporter. PEPT2. SLC15A2. Kidney. Proximal tubule. Brain. Choroid plexus. Low capacity. High affinity. Reabsorptive. Substrates. Dipeptides. Tripeptides. Peptide-like drugs. Beta-lactams. ACE inhibitors. Valacyclovir. Mechanism. H+ gradient. Driving force. Electrogenic. Charge movement. pH-dependent. Acidic environment. Optimal. Clinical relevance. Drug absorption. PEPT1 targeting. Prodrug strategy. Valyl-ester. Valacyclovir. Improved absorption. Drug-drug interactions. Competition. For transport. Renal handling. PEPT2. Reabsorption. Accumulation. In kidney. Polymorphisms. Genetic variation. Activity differences. May affect. Drug response. PEPT transporters. Are exploitable. For drug delivery. Understanding. Substrate requirements. Enables design. Of transported peptides. Prodrug approaches. Common application.

Transportadores ABC

ABC transporters efflux molecules. P-glycoprotein. MDR1. ABCB1. Most studied. Broad substrate specificity. Location. Intestine. Apical. Limits absorption. Liver. Canalicular. Biliary excretion. Kidney. Apical. Urinary excretion. Brain. Blood-brain barrier. Efflux pump. Limits CNS penetration. Substrates. Many drugs. Including peptides. Cyclosporine. HIV protease inhibitors. Mechanism. ATP-dependent. Primary active transport. Against gradient. Drug resistance. Overexpression. In cancer cells. MDR phenotype. Clinical implications. Drug interactions. P-gp inhibitors. Increase absorption. Of substrates. CNS penetration. May increase. Beneficial. Or toxic. Genetic polymorphisms. Activity variation. Drug response. Effect on peptides. Larger peptides. Not typically substrates. Smaller peptides. May be. Cyclized peptides. Some are. Cyclosporine. Classic example. Understanding P-gp. For peptides targeting. CNS. Avoid substrates. Or use inhibitors. For peripheral targets. P-gp efflux. May be beneficial. Limits CNS exposure. Reduces central side effects. Design consideration. Avoid or exploit. Depending on goal.

Transportadores de aminoacidos

Amino acid transporters handle peptides. Types. System L. LAT1. Large neutral. Aromatic. Branched chain. Upregulated. In cancer. System A. SNAT. Small neutral. Alanine. Proline. System ASC. Alanine. Serine. Cysteine. Basic aminoacidos. CAT. Cationic. Acidic aminoacidos. EAAT. Anionic. Relation to peptides. Peptide hydrolysis. Products. Aminoacidos. Free aminoacidos. From peptide breakdown. Are transported. Peptide-mimetic drugs. May use. Amino acid transporters. If similar structure. LAT1. Used by. Some drugs. L-DOPA. Melphalan. Gabapentin. Cancer targeting. LAT1 overexpression. Exploit for. Drug delivery. Peptide prodrugs. Amino acid conjugates. May use. These transporters. For absorption. Tissue distribution. Understanding. Amino acid transport. Inform design. Of peptide-based drugs. And prodrugs. Tissue-specific expression. Enables targeting. Cancer cells. Express LAT1. Highly. Drug conjugates. Can exploit. This differential expression. Selective delivery. Reduced toxicity. To normal cells.

Receptores de endocitosis

Endocytic receptors internalize peptides. Types. Receptor-mediated endocytosis. Clathrin-coated pits. Main pathway. Caveolae. Lipid rafts. Pinocytosis. Fluid-phase. Non-specific. Receptors. Transferrin receptor. Iron uptake. Exploited for. Brain delivery. Insulin receptor. Glucose regulation. Also at BBB. LDL receptor family. Lipid uptake. Includes LRP1. FcRn. IgG recycling. Albumin receptor. Megalin/cubilin. Renal reabsorption. Peptide internalization. Conjugation to ligands. Targeting receptors. Transferrin. For brain. Albumin. For half-life extension. Fc fusion. For FcRn recycling. Mechanism. Binding. Receptor clustering. Pit formation. Internalization. Endosome. Sorting. Lysosome. Degradation. Or recycling. To surface. Transcytosis. Cross barrier. BBB. Using TfR. Or IR. Therapeutic application. Brain delivery. Major challenge. Receptor targeting. Enables crossing. Limitations. Competition. With endogenous ligands. Saturation. Dose-dependent. Non-specific uptake. By other tissues. Endocytic pathways. Are exploitable. For delivery. Understanding kinetics. Saturation. Trafficking. Enables optimization. Of delivery strategies.

Transportadores organicos

Organic transporters handle diverse substrates. OATP. Organic anion transporting polypeptides. SLCO family. Substrates. Bile acids. Hormones. Drugs. Some peptides. Locations. Liver. Uptake. Brain. Kidney. Intestine. OAT. Organic anion transporters. SLC22 family. Substrates. Anionic drugs. Metabolites. Locations. Kidney. Proximal tubule. Secretion. Liver. OCT. Organic cation transporters. SLC22 family. Substrates. Cationic drugs. Locations. Liver. Kidney. Intestine. Clinical relevance. Drug uptake. Into tissues. Drug elimination. Renal secretion. Hepatic uptake. Drug interactions. Competition. For transport. Disease states. Altered expression. Chronic kidney disease. Reduced OAT. Liver disease. Reduced OATP. Effect on peptides. Charged peptides. May be substrates. For OAT/OCT. Large anionic peptides. May use OATP. Drug development. Evaluate transport. Identify substrates. Predict distribution. Elimination. Drug-drug interaction. Potential. Organic transporters. Expand repertoire. Of delivery routes. For appropriately. Charged peptides. Structure-transport. Relationships. Guide design. For desired. Tissue distribution. And clearance.

Implicaciones para diseno

Transporters inform peptide design. Absorption enhancement. PEPT1 targeting. Prodrugs. Amino acid conjugates. Improved oral bioavailability. Distribution targeting. BBB crossing. Receptor-mediated transcytosis. TfR targeting. IR targeting. Cancer targeting. LAT1 exploitation. Tumor-selective uptake. Reduced side effects. Clearance modification. Avoid efflux. P-gp substrate. Avoid for CNS. Reduce renal. Protein binding. Size increase. Drug interactions. Assess potential. Transporter competition. DDI risk. Prodrug strategies. PEPT1. For oral. Amino acid. For LAT1. For cancer. Conjugation. Albumin. Half-life. Fc. Recycling. Receptor targeting. Delivery. Design process. Identify goal. Absorption. Distribution. Clearance. Select transporter. With appropriate. Expression. Selectivity. Design peptide. Or conjugate. As substrate. Test transport. In vitro systems. Cell lines. Membrane vesicles. Optimize. Structure-activity. For transport. Integrate with. Other design goals. Activity. Stability. Safety. Transporter-based design. Is powerful. For solving. Delivery challenges. Oral absorption. CNS penetration. Tumor targeting. Successful examples. Valacyclovir. PEPT1. Albumin conjugates. Half-life. Transporter knowledge. Is enabling technology. For peptide therapeutics.

Hallazgos Clave

Más artículos en Metodología de Investigación

Más artículos en Información General

Artículos relacionados

Preguntas frecuentes

Como funciona valacyclovir como prodrug PEPT1?
Acyclovir tiene baja biodisponibilidad oral. Valacyclovir es ester valil de acyclovir. El grupo valil lo hace sustrato de PEPT1 en intestino. PEPT1 transporta el prodrug activamente, aumentando absorcion 3-5x. En sangre, esterases liberan acyclovir activo.
Que es la estrategia de receptor-mediated transcytosis?
Conjugar peptido a anticuerpo que se une a receptor endocitico en BBB (ej. TfR). El anticuerpo-peptido se internaliza, trafica a traves del endotelio, y se libera en lado cerebral. Aprovecha el sistema natural de transporte transcelular del endotelio.
Por que LAT1 es atractivo para targeting de cancer?
LAT1 transporta aminoacidos grandes neutrales. Esta sobreexpresado en muchas celulas cancerosas para soportar crecimiento rapido. Conjugados de farmacos con aminoacidos pueden usar LAT1 para entrada selectiva en tumores, reduciendo exposicion en tejidos normales.
Como afecta P-gp a peptidos terapeuticos?
Peptidos que son sustratos de P-gp son effluxados de celdas, reduciendo absorcion intestinal y penetracion en cerebro. Ciclosporina es ejemplo clasico. Para evitar: disenar no-sustratos, usar inhibidores de P-gp, o formular para bypass intestinal (inyectable).

Volver a la biblioteca de investigación